Point72 Hong Kong Ltd Decreases Holdings in Natera, Inc. (NASDAQ:NTRA)

Point72 Hong Kong Ltd lowered its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 70.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,019 shares of the medical research company’s stock after selling 2,382 shares during the period. Point72 Hong Kong Ltd’s holdings in Natera were worth $110,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of NTRA. Itau Unibanco Holding S.A. acquired a new stake in Natera in the 2nd quarter worth about $28,000. GAMMA Investing LLC lifted its position in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 108 shares in the last quarter. YHB Investment Advisors Inc. purchased a new position in shares of Natera in the first quarter valued at approximately $36,000. Tobam purchased a new position in shares of Natera in the second quarter valued at approximately $74,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Natera during the first quarter worth approximately $83,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on NTRA. Jefferies Financial Group began coverage on shares of Natera in a research note on Monday, June 3rd. They set a “buy” rating and a $142.00 target price on the stock. UBS Group dropped their price target on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. BTIG Research raised their price objective on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Canaccord Genuity Group lifted their target price on Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. Finally, Stephens reissued an “overweight” rating and issued a $125.00 price target on shares of Natera in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $120.07.

Natera Stock Up 1.5 %

Shares of Natera stock opened at $125.72 on Friday. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $132.01. The company has a 50 day moving average of $115.98 and a 200 day moving average of $106.51. The company has a market capitalization of $15.44 billion, a P/E ratio of -40.29 and a beta of 1.53. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same quarter last year, the company earned ($0.97) EPS. The business’s quarterly revenue was up 58.1% on a year-over-year basis. As a group, research analysts forecast that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Insider Activity at Natera

In other Natera news, insider Daniel Rabinowitz sold 1,057 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $102.77, for a total value of $108,627.89. Following the completion of the sale, the insider now owns 206,400 shares in the company, valued at $21,211,728. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $108.87, for a total value of $293,949.00. Following the sale, the insider now owns 301,808 shares of the company’s stock, valued at $32,857,836.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Daniel Rabinowitz sold 1,057 shares of Natera stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $102.77, for a total value of $108,627.89. Following the completion of the sale, the insider now directly owns 206,400 shares in the company, valued at approximately $21,211,728. The disclosure for this sale can be found here. Insiders sold a total of 93,921 shares of company stock valued at $10,551,281 over the last ninety days. Insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.